Cagrilintide 10mg
Cagrilintide
CAS: 2381089-29-0
Cagrilintide is a long-acting amylin analog (AMY1/AMY3 receptor agonist) with a 7-day half-life achieved via C20 fatty diacid acylation. COMBINE 2 trial: CagriSema (cagrilintide + semaglutide) achieved -22.7% body weight at 32 weeks. >98.8% HPLC purity.
Specifications
For laboratory research use only. Not for human consumption.
Mechanism of Action
Agonizes amylin receptors (AMY1/AMY3) in the area postrema and hypothalamus to suppress appetite through a neural circuit entirely independent of GLP-1R signaling, enabling additive effects when combined with GLP-1 agonists.
Research FAQ
How does cagrilintide work alongside semaglutide?
Cagrilintide targets amylin receptors (brainstem/area postrema pathway) while semaglutide targets GLP-1R (hypothalamic pathway). Independent circuits produce additive appetite suppression — the basis of the CagriSema combination.
What is the half-life of cagrilintide?
Approximately 7 days, achieved via C20 fatty diacid modification that enables albumin binding — similar to semaglutide's acylation strategy.
